1. Shah VP. Progress in methodologies for evaluating bioequivalence of topical formulations. Am J Clin Dermatol. 2001;2(5):275–80.
2. Kanfer I. Strategies for the bioequivalence assessment of topical dermatological dosage forms. J Bioequivalence Availab. 2010;2:102–10. doi: 10.4172/ jbb.1000040 .
3. Kircik LH, Bikowski JB, Cohen DE, Draelos ZD, Hebert A. Formulation development, testing and approval, part 1 of 2. Supplement to practical dermatology. Vehicles matter. 2010. http://bmctoday.net/vehiclesmatter/pdfs/0310.pdf . Accessed 18 Apr 2014.
4. General Chapter <1151> Pharmaceutical dosage forms. US Pharmacoepia. 2013. http://www.uspnf.com/uspnf/pub/index?usp=36&nf=31&s=2&officialOn=December 1, 2013 . Accessed 18 April 2014.
5. Shah VP, Flynn GL, Yacobi A, Maibach HI, Bon C, et al. Bioequivalence of topical dermatological dosage forms—methods of evaluation of bioequivalence. Pharm Res. 1998;15(2):167–71. doi: 10.1023/A:1011941929495 .